545 related articles for article (PubMed ID: 17935664)
1. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
3. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
5. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
8. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
9. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
13. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
16. DNA-image cytometry and clinical staging systems in multiple myeloma.
Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
[TBL] [Abstract][Full Text] [Related]
17. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
18. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
Shimamoto Y
Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
[TBL] [Abstract][Full Text] [Related]
19. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
Li J; Wu XB; Zhou Y; Wang X; Chen JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
